Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity. GSBR-1290 is an orally-available, nonpeptide small molecule glucagon-like-peptide-1 receptor agonist that has demonstrated competitive weight loss and generally favorable safety and tolerability results in previous studies with once-daily dosing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Is GPCR a Buy, Before Earnings?
- 3 Best Stocks to Buy Now, 9/23/2024, According to Top Analysts
- Structure Therapeutics initiated with an Overweight at Morgan Stanley
- Structure Therapeutics Announces Key Executive Leadership Changes
- Structure Therapeutics CMO Mark Bach to leave role, Blai Coll to succed